David P. Schenkein - 22 Feb 2022 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Role
Director
Signature
/s/ William Cook, as Attorney in Fact for David Schenkein
Issuer symbol
AGIO
Transactions as of
22 Feb 2022
Net transactions value
-$22,043
Form type
4
Filing time
23 Feb 2022, 15:09:46 UTC
Previous filing
04 Jun 2021
Next filing
24 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGIO Common stock Options Exercise $0 +2,775 +2.4% $0.000000 117,052 22 Feb 2022 Direct
transaction AGIO Common stock Tax liability $22,043 -758 -0.65% $29.08 116,294 22 Feb 2022 Direct
holding AGIO Common stock 79,082 22 Feb 2022 See footnote F1
holding AGIO Common stock 270,772 22 Feb 2022 See footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGIO Restricted stock units Options Exercise $0 -2,775 -100% $0.000000* 0 22 Feb 2022 Common stock 2,775 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.
F2 Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.
F3 Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F4 The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments.